Dr Chrissy Muttiah - ACRF Cancer Biology & Stem Cells division

Dr Chrissy Muttiah - ACRF Cancer Biology & Stem Cells division

Davis Auditorium
Start Time: 
Wed, 30/11/2022 - 3:00pm
End Time: 
Wed, 30/11/2022 - 4:00pm

WEHI Masters Completion Seminar hosted by Professor Geoff Lindeman

Dr Chrissy Muttiah

of Philosophy (MPhil), Breast Cancer Laboratory, ACRF Cancer Biology
& Stem Cells division – Cancer Research & Treatments Theme, WEHI


The Role of Venetoclax in the Treatment of Breast Cancer


Davis Auditorium

Join via TEAMS

Including Q&A session


of cell death is a hallmark of cancer. Targeting members of the BCL2
pro-survival family is a promising strategy to treat certain blood
cancers but has yet to be properly evaluated in solid tumours. BCL-2 is
overexpressed in the majority of oestrogen receptor positive (ER+)
breast cancer and commonly expressed in triple negative breast cancer
(TNBC). This thesis describes the investigation of venetoclax, an
inhibitor of BCL-2, in the treatment of ER+ and TNBC through phase 1
clinical trials.

Christine Muttiah is a medical oncologist, Breast Cancer Trial Fellow
and a M. Phil candidate through WEHI and the University of Melbourne.
She is involved in investigator-initiated trials of novel breast cancer
treatments and breast cancer prevention studies.


All welcome!